Current Evidence and Clinical Insights

Video content above is prompted by the following:

Fezolinetant, another neurokinin-3 receptor antagonist, has been evaluated in 52-week clinical studies involving postmenopausal women with moderate to severe vasomotor symptoms. Current available data indicates that fezolinetant has a neutral effect on bone density and bone health, neither improving nor worsening skeletal outcomes.

This neutral bone health profile distinguishes fezolinetant from elinzanetant, which showed potential bone benefits in the OASIS-3 trial. The difference may relate to the specific receptor targeting, as fezolinetant acts solely on NK-3 receptors while elinzanetant targets both NK-1 and NK-3 receptors.

The neutral bone health effects of fezolinetant, while not providing additional skeletal benefits, may still represent an acceptable profile for women primarily seeking vasomotor symptom relief without estrogen therapy. This positions fezolinetant as a viable option for symptom management while maintaining bone health status quo.